Cytosorbents’ (CTSO) Buy Rating Reaffirmed at D. Boral Capital

Cytosorbents (NASDAQ:CTSO)‘s stock had its “buy” rating reissued by D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They currently have a $10.00 target price on the medical research company’s stock.

CTSO has been the subject of several other reports. HC Wainwright reduced their price objective on Cytosorbents from $1.00 to $0.75 and set a “neutral” rating for the company in a report on Friday, November 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cytosorbents in a research note on Tuesday, October 14th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $5.38.

Cytosorbents Price Performance

Shares of NASDAQ CTSO traded up $0.02 during midday trading on Tuesday, hitting $0.65. The company had a trading volume of 53,690 shares, compared to its average volume of 160,718. The firm has a market capitalization of $40.63 million, a price-to-earnings ratio of -3.59 and a beta of 1.28. Cytosorbents has a twelve month low of $0.60 and a twelve month high of $1.61. The business has a 50-day simple moving average of $0.78 and a two-hundred day simple moving average of $0.93. The company has a quick ratio of 1.71, a current ratio of 2.11 and a debt-to-equity ratio of 1.61.

Cytosorbents (NASDAQ:CTSO) last issued its earnings results on Friday, January 3rd. The medical research company reported ($0.08) earnings per share (EPS) for the quarter. Cytosorbents had a negative net margin of 27.77% and a negative return on equity of 101.14%. The company had revenue of $8.61 million during the quarter. Equities research analysts anticipate that Cytosorbents will post -0.3 earnings per share for the current year.

Hedge Funds Weigh In On Cytosorbents

A number of institutional investors have recently modified their holdings of CTSO. Citadel Advisors LLC lifted its stake in shares of Cytosorbents by 127.3% during the third quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock valued at $61,000 after buying an additional 36,790 shares during the period. Goldman Sachs Group Inc. raised its holdings in Cytosorbents by 149.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after acquiring an additional 37,519 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Cytosorbents during the 3rd quarter worth $105,000. CIBC Bancorp USA Inc. purchased a new position in shares of Cytosorbents during the 3rd quarter worth $161,000. Finally, CM Management LLC boosted its holdings in shares of Cytosorbents by 3.1% during the third quarter. CM Management LLC now owns 1,288,128 shares of the medical research company’s stock worth $1,203,000 after purchasing an additional 38,128 shares during the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.